AU2015348944A1 - Substituted bridged urea analogs as sirtuin modulators - Google Patents

Substituted bridged urea analogs as sirtuin modulators Download PDF

Info

Publication number
AU2015348944A1
AU2015348944A1 AU2015348944A AU2015348944A AU2015348944A1 AU 2015348944 A1 AU2015348944 A1 AU 2015348944A1 AU 2015348944 A AU2015348944 A AU 2015348944A AU 2015348944 A AU2015348944 A AU 2015348944A AU 2015348944 A1 AU2015348944 A1 AU 2015348944A1
Authority
AU
Australia
Prior art keywords
branched
straight
heterocyclyl
haloalkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2015348944A
Other languages
English (en)
Inventor
James Lamond ELLIS
Karen Anderson Evans
Ryan Michael Fox
William Henry Miller
Mark Andrew Seefeld
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property No 2 Ltd
Original Assignee
GlaxoSmithKline Intellectual Property No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property No 2 Ltd filed Critical GlaxoSmithKline Intellectual Property No 2 Ltd
Publication of AU2015348944A1 publication Critical patent/AU2015348944A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2015348944A 2014-11-19 2015-11-19 Substituted bridged urea analogs as sirtuin modulators Abandoned AU2015348944A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462081916P 2014-11-19 2014-11-19
US62/081,916 2014-11-19
PCT/IB2015/058981 WO2016079712A1 (en) 2014-11-19 2015-11-19 Substituted bridged urea analogs as sirtuin modulators

Publications (1)

Publication Number Publication Date
AU2015348944A1 true AU2015348944A1 (en) 2017-06-01

Family

ID=54705247

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2015348944A Abandoned AU2015348944A1 (en) 2014-11-19 2015-11-19 Substituted bridged urea analogs as sirtuin modulators
AU2015348942A Ceased AU2015348942B2 (en) 2014-11-19 2015-11-19 Substituted bridged urea analogs as sirtuin modulators
AU2015348941A Abandoned AU2015348941A1 (en) 2014-11-19 2015-11-19 Substituted bridged urea analogs as Sirtuin Modulators
AU2015348943A Abandoned AU2015348943A1 (en) 2014-11-19 2015-11-19 Substituted bridged urea analogs as sirtuin modulators

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2015348942A Ceased AU2015348942B2 (en) 2014-11-19 2015-11-19 Substituted bridged urea analogs as sirtuin modulators
AU2015348941A Abandoned AU2015348941A1 (en) 2014-11-19 2015-11-19 Substituted bridged urea analogs as Sirtuin Modulators
AU2015348943A Abandoned AU2015348943A1 (en) 2014-11-19 2015-11-19 Substituted bridged urea analogs as sirtuin modulators

Country Status (21)

Country Link
US (4) US20170355705A1 (enExample)
EP (4) EP3221317B1 (enExample)
JP (4) JP2017534663A (enExample)
KR (4) KR20170087907A (enExample)
CN (4) CN107207520A (enExample)
AU (4) AU2015348944A1 (enExample)
BR (4) BR112017010602A2 (enExample)
CA (4) CA2968032A1 (enExample)
CL (1) CL2017001275A1 (enExample)
CO (1) CO2017004994A2 (enExample)
CR (1) CR20170209A (enExample)
DO (1) DOP2017000123A (enExample)
EA (1) EA201791074A1 (enExample)
ES (1) ES2823748T3 (enExample)
IL (1) IL252252A0 (enExample)
MX (1) MX2017006658A (enExample)
PE (1) PE20171257A1 (enExample)
PH (1) PH12017500913A1 (enExample)
RU (3) RU2017120855A (enExample)
SG (1) SG11201703824QA (enExample)
WO (4) WO2016079712A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016086088A2 (en) 2014-11-25 2016-06-02 Northwestern University Wound healing through sirt1 overexpression
CN108329388A (zh) * 2018-01-18 2018-07-27 天津市湖滨盘古基因科学发展有限公司 一种人的沉默配型信息调节蛋白突变蛋白及其应用
CN108707150B (zh) * 2018-05-14 2021-04-16 江苏惠利生物科技有限公司 一种咪唑并吡嗪医药中间体的制备方法
CN108395436B (zh) * 2018-05-14 2021-01-12 鹤壁市人民医院 一种咪唑并吡嗪医药中间体的制备方法
CN110478339A (zh) * 2019-08-12 2019-11-22 昆明理工大学 紫铆因在制备靶向恢复突变p53构象药物中的应用
EP4025566A1 (de) * 2019-09-02 2022-07-13 Merck Patent GmbH Materialien für organische elektrolumineszenzvorrichtungen
BR112022009649A2 (pt) * 2019-11-19 2022-08-16 Lupin Ltd Processo, intermediários e métodos para preparar compostos de cromano
FI4090654T3 (fi) * 2020-01-17 2025-09-30 Lupin Ltd Menetelmiä, prosesseja ja välituotteita kromaaniyhdisteiden valmistamiseksi
CN114890955A (zh) * 2022-06-23 2022-08-12 江西瑞威尔生物科技有限公司 一种n取代吗啉类有机化合物的制备工艺

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO2006094210A2 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Tetrahydroquinoxalinone sirtuin modulators
UA108596C2 (xx) 2007-11-09 2015-05-25 Інгібітори пептиддеформілази
CA2779303A1 (en) * 2009-10-29 2011-05-19 Sirtris Pharmaceuticals, Inc. Bicyclic pyridines and analogs as sirtuin modulators
AU2012352442A1 (en) * 2011-12-12 2014-07-03 Smb Innovation Aps Novel heterocyclic compounds useful in sirtuin binding and modulation
WO2014186313A1 (en) * 2013-05-13 2014-11-20 Glaxosmithkline Llc Substituted bridged urea analogs as sirtuin modulators

Also Published As

Publication number Publication date
CA2968030A1 (en) 2016-05-26
WO2016079709A1 (en) 2016-05-26
BR112017010601A2 (pt) 2017-12-26
RU2017120857A (ru) 2018-12-19
CN107108627A (zh) 2017-08-29
JP6806679B2 (ja) 2021-01-06
BR112017010595A2 (pt) 2018-01-02
EP3221317B1 (en) 2020-07-22
US20190048016A1 (en) 2019-02-14
WO2016079711A1 (en) 2016-05-26
DOP2017000123A (es) 2017-08-15
KR20170087907A (ko) 2017-07-31
CA2968027A1 (en) 2016-05-26
CA2968029A1 (en) 2016-05-26
US20170355705A1 (en) 2017-12-14
RU2017120855A (ru) 2018-12-19
CN107207509B (zh) 2020-04-21
AU2015348942B2 (en) 2018-07-05
PE20171257A1 (es) 2017-08-28
CO2017004994A2 (es) 2017-09-20
RU2017120858A (ru) 2018-12-19
EP3221322A1 (en) 2017-09-27
US10072011B2 (en) 2018-09-11
MX2017006658A (es) 2018-01-15
JP2017534665A (ja) 2017-11-24
CR20170209A (es) 2017-07-17
CN107207520A (zh) 2017-09-26
WO2016079712A1 (en) 2016-05-26
AU2015348942A1 (en) 2017-06-01
EP3220918A1 (en) 2017-09-27
ES2823748T3 (es) 2021-05-10
EP3221317A1 (en) 2017-09-27
CN107207509A (zh) 2017-09-26
KR20170083133A (ko) 2017-07-17
IL252252A0 (en) 2017-07-31
US20170362234A1 (en) 2017-12-21
KR20170083135A (ko) 2017-07-17
JP2017534664A (ja) 2017-11-24
PH12017500913A1 (en) 2017-12-04
JP2017534662A (ja) 2017-11-24
BR112017010602A2 (pt) 2017-12-26
CN107207521A (zh) 2017-09-26
BR112017010599A2 (pt) 2017-12-26
CA2968032A1 (en) 2016-05-26
CL2017001275A1 (es) 2017-12-15
EA201791074A1 (ru) 2017-10-31
WO2016079710A1 (en) 2016-05-26
AU2015348943A1 (en) 2017-06-01
KR20170083134A (ko) 2017-07-17
AU2015348941A1 (en) 2017-06-01
JP2017534663A (ja) 2017-11-24
US20180319810A1 (en) 2018-11-08
EP3221316A1 (en) 2017-09-27
SG11201703824QA (en) 2017-06-29

Similar Documents

Publication Publication Date Title
US10590135B2 (en) Substituted bridged urea analogs as sirtuin modulators
US10072011B2 (en) Substituted bridged urea analogs as sirtuin modulators
WO2016081692A2 (en) Substituted bridged urea analogs as sirtuin modulators

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted